Arca
Skip to content

Hybrid Viewer (00859873006240)

System, Tomography, Computed, Emission. 510(k) K252477, from Hermes Medical Solutions AB (Stockholm, SE). Product code KPS, class 2.

As of Nov 17, 2026, K252477 is an FDA 510(k) held by Hermes Medical Solutions AB, substantially equivalent on Sep 9, 2025 after 33 days, with no recalls tied to it in FDA's recall database.

  • Substantially equivalent: Sep 9, 2025
  • Review time: 33 days
  • Recalls: 0

Indications for Use

As the 510(k) summary states them, read from FDA's summary PDF

Hybrid Viewer is a software application for nuclear medicine and radiology. Based on user input, Hybrid Viewer processes, displays and analyzes nuclear medicine and radiology imaging data and presents the results to the user. The results can be stored for future analysis.

Predicate Devices

The legally marketed devices this 510(k) summary says it is substantially equivalent to, read from FDA's summary PDF

Other KPS Clearances

The newest 510(k)s for the same product code; their median review was 88 days; see every KPS device

Record

Type
Special
Received
Aug 7, 2025
Review panel
Radiology
Regulation
21 CFR 892.1200

One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.